IL17A and psoriasis: Interleukin-17 inhibitor therapy showed a great impact on the flow-mediated dilatation (FMD) in the Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated with Secukinumab (CARIMA), according to a study and on the perivascular fat attenuation index (FAI), which are indicators of early atherosclerotic changes [34,35].